Hypersomnia in Mood Disorders: a Rapidly Changing Landscape

Current Sleep Medicine Reports

Volumn 1, Issue 2, 2015, Pages 122-130

  Plante, David T ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Section of Allergy   (United States)

Author keywords

Arousal; Depression; Hypersomnia; Mood disorders; Nosology; Sleepiness

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ARMODAFINIL; DEXAMPHETAMINE; GLUCOCORTICOID; MIRTAZAPINE; MODAFINIL; SEROTONIN UPTAKE INHIBITOR;

ACTIMETRY; CLINICAL TRIAL (TOPIC); DAYTIME SOMNOLENCE; DEPRESSION; DSM-5; EPWORTH SLEEPINESS SCALE; FATIGUE; GENETIC POLYMORPHISM; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPERPHAGIA; HYPERSOMNIA; INSOMNIA; INTERNATIONAL CLASSIFICATION OF SLEEP DISORDERS; MOOD DISORDER; OVERNUTRITION; POLYSOMNOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DEPRIVATION; SLEEP TIME; SOCIAL PSYCHOLOGY; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 84969162972     PISSN: None     EISSN: 21986401     Source Type: Journal    
DOI: 10.1007/s40675-015-0017-9     Document Type: Review

References (75)

1. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475(7354):27–30.
2. Worthington J, Fava M, Davidson K, Alpert J, Nierenberg AA, Rosenbaum JF. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull. 1995;31(2):223–6.
3. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Differences between minimally depressed patients who do and do not consider themselves to be in remission. J Clin Psychiatry. 2005;66(9):1134–8.
4. Kaplan KA, Harvey AG. Hypersomnia across mood disorders: a review and synthesis. Sleep Med Rev. 2009;13(4):275–85.
5. Kaplan KA, Gruber J, Eidelman P, Talbot LS, Harvey AG. Hypersomnia in inter-episode bipolar disorder: does it have prognostic significance? J Affect Disord. 2011;132(3):438–44.
6. Goldstein TR, Bridge JA, Brent DA. Sleep disturbance preceding completed suicide in adolescents. J Consult Clin Psychol. 2008;76(1):84–91.
7. Fitzgerald CT, Messias E, Buysse DJ. Teen sleep and suicidality: results from the youth risk behavior surveys of 2007 and 2009. J Clin Sleep Med. 2011;7(4):351–6.
8. Dauvilliers Y, Lopez R, Ohayon M, Bayard S. Hypersomnia and depressive symptoms: methodological and clinical aspects. BMC Med. 2013;11:78.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
10. American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
11. American Academy of Sleep Medicine: International classification of sleep disorders: diagnostic and coding manual. 2nd ed. Darien, IL: American Academy of Sleep Medicine; 2005.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000.
13. Ohayon MM, Dauvilliers Y, Reynolds 3rd CF. Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology. Arch Gen Psychiatry. 2012;69(1):71–9. Large epidemiologic study that examined the prevalence of excessive sleepiness and hypersomnolence disorder in the U.S. population.
14. Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473–81.
15. Ohayon MM, Roberts LW. Challenging the validity of the association between oversleeping and overeating in atypical depression. J Psychosom Res. 2015;78(1):52–7. Cross-sectional epidemiologic study examining the prevalence of depression and associated symptoms that showed no association between hypersomnia and other symptoms of atypical depression when hypersomnia was strictly defined.
16. Ohayon MM, Reynolds CF, Dauvilliers Y. Excessive sleep duration and quality of life. Ann Neurol. 2013;73(6):785–94. Large epidemiologic study that determined the population prevalence of sleeping greater than 9 hours per night with associated distress/impairment (1.6%), with the likelihood of these symptoms 3–12-fold higher among individuals with a mood disorder.
17. Fried EI, Nesse RM. The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS ONE. 2014;9(2):e90311.
18. Soehner AM, Kaplan KA, Harvey AG. Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. J Affect Disord. 2014;167:93–7. Analysis of data from the National Comorbidity Survey Replication demonstrating co-occurring excessive sleep time and insomnia were associated with more severe major depressive episode.
19. Fernandez-Mendoza J, N A, Kritikou I, L S, Liao D, Bixler EO: Natural History of Excessive Daytime Sleepiness: Role of Obesity, Weight Loss, Depression, and Sleep Propensity. Sleep. 2015;38(3):351–60. Using longitudinal data from the Penn State Adult Cohort, demonstrated sleep disturbance predicted incident daytime sleepiness in depressed individuals, which was opposite factors associated with incident sleepiness among non-depressed individuals.
20. Kaplan KA, McGlinchey EL, Soehner A, et al.: Hypersomnia subtypes, sleep and relapse in bipolar disorder. Psychol Med. 2014:1–13. In Press. Longitudinal analysis of a community sample of patients with bipolar disorder that described two separate (and uncorrelated) subtypes of hypersomnia, long sleep and excessive sleepiness, of which only the latter was associated with relapse to mania/hypomania.
21. Watson NF, Harden KP, Buchwald D, et al. Sleep duration and depressive symptoms: a gene-environment interaction. Sleep. 2014;37(2):351–8. Using data from a large twin registry, demonstrated increased genetic influence on depressive symptoms among those with both short and long sleep duration.
22. Lessov-Schlaggar CN, Bliwise DL, Krasnow RE, Swan GE, Reed T. Genetic association of daytime sleepiness and depressive symptoms in elderly men. Sleep. 2008;31(8):1111–7.
23. He Y, Jones CR, Fujiki N, et al. The transcriptional repressor DEC2 regulates sleep length in mammals. Science. 2009;325(5942):866–70.
24. Partonen T, Treutlein J, Alpman A, et al. Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. Ann Med. 2007;39(3):229–38.
25. Allebrandt KV, Amin N, Müller-Myhsok B, et al. A K(ATP) channel gene effect on sleep duration: from genome-wide association studies to function in Drosophila. Mol Psychiatry. 2013;18(1):122–32.
26. Parsons MJ, Lester KJ, Barclay NL, Nolan PM, Eley TC, Gregory AM. Replication of genome-wide association studies (GWAS) loci for sleep in the British G1219 cohort. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(5):431–8.
27. Benedetti F, Serretti A, Colombo C, et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry. 1999;156(9):1450–2.
28. Carskadon MA, Sharkey KM, Knopik VS, McGeary JE. Short sleep as an environmental exposure: a preliminary study associating 5-HTTLPR genotype to self-reported sleep duration and depressed mood in first-year university students. Sleep. 2012;35(6):791–6.
29. Allebrandt KV, Teder-Laving M, Akyol M, et al. CLOCK gene variants associate with sleep duration in two independent populations. Biol Psychiatry. 2010;67(11):1040–7.
30. Fan M, Liu B, Jiang T, Jiang X, Zhao H, Zhang J. Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. Psychiatr Genet. 2010;20(1):1–7.
31. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet. 1998;103(3):273–9.
32. Ojeda DA, Niño CL, López-León S, Camargo A, Adan A, Forero DA. A functional polymorphism in the promoter region of MAOA gene is associated with daytime sleepiness in healthy subjects. J Neurol Sci. 2014;337(1–2):176–9.
33. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257–63.
34. Aklillu E, Karlsson S, Zachrisson OO, Ozdemir V, Agren H. Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. Pharmacogenet Genomics. 2009;19(4):267–75.
35. Zalsman G, Huang YY, Harkavy-Friedman JM, Oquendo MA, Ellis SP, Mann JJ. Relationship of MAO-A promoter (u-VNTR) and COMT (V158M) gene polymorphisms to CSF monoamine metabolites levels in a psychiatric sample of Caucasians: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;132B(1):100–3.
36. Ducci F, Newman TK, Funt S, Brown GL, Virkkunen M, Goldman D. A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index. Mol Psychiatry. 2006;11(9):858–66.
37. Shih JC, Wu JB, Chen K. Transcriptional regulation and multiple functions of MAO genes. J Neural Transm. 2011;118(7):979–86.
38. Le Dantec Y, Hache G, Guilloux JP, et al. NREM sleep hypersomnia and reduced sleep/wake continuity in a neuroendocrine mouse model of anxiety/depression based on chronic corticosterone administration. Neuroscience. 2014;274:357–68. Describes a neuroendocrine mouse model of depression in which corticosterone administration results in increased sleep time and intrusion of NREM sleep into the active phase of the animal.
39. Ou XM, Chen K, Shih JC. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem. 2006;281(30):21512–25.
40. Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry. 2015;20(1):32–47.
41. Chiuccariello L, Houle S, Miler L, et al. Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms. Neuropsychopharmacology. 2014;39(4):973–80.
42. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry. 2013;18(6):692–9.
43. Plante DT, Landsness EC, Peterson MJ, et al. Altered slow wave activity in major depressive disorder with hypersomnia: a high density EEG pilot study. Psychiatry Res. 2012;201(3):240–4.
44. Aeschbach D, Sher L, Postolache TT, Matthews JR, Jackson MA, Wehr TA. A longer biological night in long sleepers than in short sleepers. J Clin Endocrinol Metab. 2003;88(1):26–30.
45. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82(5):1313–6.
46. Keating GM, Raffin MJ. Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs. 2005;19(9):785–803.
47. Garnock-Jones KP, Dhillon S, Scott LJ. Armodafinil. CNS Drugs. 2009;23(9):793–803.
48. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–7.
49. Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363–70.
50. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Group MiDS: adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057–64.
51. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85–93.
52. Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(6):614–9.
53. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8):1242–9.
54. McElroy SL, Martens BE, Mori N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(1):6–13.
55. Grunze H. Stimulants for treating bipolar disorder: pro and con. Harv Rev Psychiatry. 2014;22(6):358–62.
56. Corp SA, Gitlin MJ, Altshuler LL. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry. 2014;75(9):1010–8.
57. Sakurai H, Uchida H, Abe T, et al. Trajectories of individual symptoms in remitters versus non-remitters with depression. J Affect Disord. 2013;151(2):506–13.
58. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66(8):974–81.
59. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60(12):1350–5.
60. Cooper JA, Tucker VL, Papakostas GI. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol. 2014;28(2):118–24.
61. Shen J, Hossain N, Streiner DL, et al. Excessive daytime sleepiness and fatigue in depressed patients and therapeutic response of a sedating antidepressant. J Affect Disord. 2011;134(1–3):421–6.
62. Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry. 2006;51(1):27–34.
63. Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31(4):832–44.
64. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995;10 (Suppl 4):19–23.
65. Dijk DJ. Slow-wave sleep deficiency and enhancement: implications for insomnia and its management. World J Biol Psychiatry. 2010;11 (Suppl 1):22–8.
66. Nofzinger EA, Thase ME, Reynolds 3rd CF, et al. Hypersomnia in bipolar depression: a comparison with narcolepsy using the multiple sleep latency test. Am J Psychiatry. 1991;148(9):1177–81.
67. Dolenc L, Besset A, Billiard M. Hypersomnia in association with dysthymia in comparison with idiopathic hypersomnia and normal controls. Pflugers Arch - Eur J Physiol. 1996;431(6 Suppl 2):R303–4.
68. Billiard M, Dolenc L, Aldaz C, Ondze B, Besset A. Hypersomnia associated with mood disorders: a new perspective. J Psychosom Res. 1994;38 Suppl 1:41–7.
69. Kofmel NC, Schmitt WJ, Hess CW, Gugger M, Mathis J. Sleepiness and performance is disproportionate in patients with non-organic hypersomnia in comparison to patients with narcolepsy and mild to moderate obstructive sleep apnoea. Neuropsychobiology. 2014;70(3):189–94. Compared objective measures of sleepiness and performance in patients with non-organic hypersomnia, narcolepsy, and sleep apnea, demonstrating patients with hypersomnia associated with a psychiatric disorder had a disproportionately high error rate on the Steer Clear performance test.
70. Sangal RB, Thomas L, Mitler MM. Maintenance of wakefulness test and multiple sleep latency test. Measurement of different abilities in patients with sleep disorders. Chest. 1992;101(4):898–902.
71. Sullivan SS, Kushida CA. Multiple sleep latency test and maintenance of wakefulness test. Chest. 2008;134(4):854–61.
72. Peter-Derex L, Perrin F, Petitjean T, Garcia-Larrea L, Bastuji H. Discriminating neurological from psychiatric hypersomnia using the forced awakening test. Neurophysiol Clin. 2013;43(3):171–9. Using auditory evoked potentials during a forced awakening nap protocol, demonstrated patients with hypersomnia associated with a mood disorder did not have objectively measured excessive sleep inertia compared to other disorders of hypersomnolence.
73. Findley L, Unverzagt M, Guchu R, Fabrizio M, Buckner J, Suratt P. Vigilance and automobile accidents in patients with sleep apnea or narcolepsy. Chest. 1995;108(3):619–24.
74. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126.
75. Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014;171(4):395–7.